Cargando…

The “One-to-Many” Survival Analysis to Evaluate a New Treatment in Comparison With Therapeutic Alternatives Based on Reconstructed Patient Data: Enfortumab Vedotin Versus Standard of Care in Advanced or Metastatic Urothelial Carcinoma

Objective This paper presents a preliminary experience based on the "one-to-many" approach of the Shiny method. Numerous (or "many") treatments for advanced or metastatic urothelial carcinoma have recently been reviewed. More recently, "one" potentially innovative treat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Messori, Andrea, Rivano, Melania, Cancanelli, Luca, Damuzzo, Vera, Ossato, Andrea, Chiumente, Marco, Mengato, Daniele
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cureus 2022
Materias:	Urology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9508613/ https://www.ncbi.nlm.nih.gov/pubmed/36171827 http://dx.doi.org/10.7759/cureus.28369

Ejemplares similares

Application of the IPDfromKM-Shiny Method to Compare the Efficacy of Novel Treatments Aimed at the Same Disease Condition: A Report of 14 Analyses
por: Messori, Andrea, et al.
Publicado: (2023)

Progression-Free and Overall Survival of First-Line Treatments for Advanced Renal Cell Carcinoma: Indirect Comparison of Six Combination Regimens
por: Ossato, Andrea, et al.
Publicado: (2023)

Efficacy of Immune Checkpoint Inhibitors in Patients with Mismatch Repair-Deficient or Microsatellite Instability-High Metastatic Colorectal Cancer: Analysis of Three Phase-II Trials
por: Cancanelli, Luca, et al.
Publicado: (2021)

Immune checkpoint inhibitors as first line in advanced melanoma: Evaluating progression‐free survival based on reconstructed individual patient data
por: Ossato, Andrea, et al.
Publicado: (2022)

The Degree of Programmed Death-Ligand 1 (PD-L1) Positivity as a Determinant of Outcomes in Metastatic Triple-Negative Breast Cancer Treated With First-Line Immune Checkpoint Inhibitors
por: Di Spazio, Lorenzo, et al.
Publicado: (2022)

Survival in Patients with Relapsed-Refractory Multiple Myeloma: Indirect Comparison of Six New Treatments
por: Cancanelli, Luca, et al.
Publicado: (2023)

Enfortumab Vedotin in urothelial cancer
por: Alt, Marie, et al.
Publicado: (2020)

Temporary Tumor Shrinkage Following Enfortumab Vedotin Therapy for Metastatic Urothelial Carcinoma After Radical Cystectomy With Neoadjuvant Chemotherapy: A Case Report
por: Namiki, Sanae, et al.
Publicado: (2023)

Treatments for Relapsed-Refractory Diffuse Large B-cell Lymphoma: A Preliminary Evaluation of the Place in Therapy of Glofitamab, a Bispecific Monoclonal Antibody
por: Messori, Andrea, et al.
Publicado: (2022)

Cost-effectiveness of enfortumab vedotin in previously treated advanced urothelial carcinoma
por: Wu, Qiuji, et al.
Publicado: (2022)

Enfortumab vedotin in metastatic urothelial carcinoma: the solution EVentually?
por: Maiorano, Brigida Anna, et al.
Publicado: (2023)

COVID-19 impact on skills and professional perceptions of the hospital pharmacist during the first outbreak wave
por: Damuzzo, Vera, et al.
Publicado: (2022)

The QOSMOS Study: Pharmacist-Led Multicentered Observational Study on Quality of Life in Multiple Sclerosis
por: Damuzzo, Vera, et al.
Publicado: (2021)

Analysis of Survival Curves: Statistical Methods Accounting for the Presence of Long-Term Survivors
por: Damuzzo, Vera, et al.
Publicado: (2019)

Administration of Enfortumab Vedotin after Immune-Checkpoint Inhibitor and the Prognosis in Japanese Metastatic Urothelial Carcinoma: A Large Database Study on Enfortumab Vedotin in Metastatic Urothelial Carcinoma
por: Kawahara, Takashi, et al.
Publicado: (2023)

Profile of Enfortumab Vedotin in the Treatment of Urothelial Carcinoma: The Evidence to Date
por: Moussa, Mohamad, et al.
Publicado: (2021)

Targeted Treatment of Locally Advanced and Metastatic Urothelial Cancer: Enfortumab Vedotin in Context
por: Hoffman-Censits, Jean, et al.
Publicado: (2022)

Current and Emerging Treatments for Urothelial Carcinoma: A Focus on Enfortumab Vedotin
por: Shafique, Muhammad Ashir, et al.
Publicado: (2023)

Drug extravasation with Enfortumab vedotin
por: Grant, Christopher Ryan, et al.
Publicado: (2023)

Emerging Treatment Options for the Treatment of Metastatic Urothelial Cancer: Therapeutic Potential of Enfortumab Vedotin
por: Jain, Rohit K, et al.
Publicado: (2020)

Severe cutaneous drug toxicity following enfortumab vedotin treatment for metastatic urothelial carcinoma
por: Enescu, Christina D., et al.
Publicado: (2022)

FGFR2/3 genomic alterations and response to Enfortumab Vedotin in metastatic urothelial carcinoma
por: Adib, Elio, et al.
Publicado: (2021)

First Evidence of Activity of Enfortumab Vedotin on Brain Metastases in Urothelial Cancer Patients
por: Vulsteke, Christof, et al.
Publicado: (2023)

Flexural Exanthema From Enfortumab Vedotin
por: Keerty, Dinesh, et al.
Publicado: (2020)

Toxic epidermal necrolysis after the administration of enfortumab vedotin for urinary bladder urothelial carcinoma
por: Mimura, Yuji, et al.
Publicado: (2022)

Axicabtagene ciloleucel in non-Hodgkin lymphoma: the restricted mean survival time as a tool for estimating progression-free life expectancy better than the median
por: Messori, Andrea, et al.
Publicado: (2020)

A phase I study of enfortumab vedotin in Japanese patients with locally advanced or metastatic urothelial carcinoma
por: Takahashi, Shunji, et al.
Publicado: (2019)

Complete Response to Enfortumab Vedotin in a Hemodialysis Patient with Metastatic Urothelial Carcinoma: A Case Report
por: Isoda, Bunpei, et al.
Publicado: (2023)

Advancements in Therapy for Bladder Cancer: Enfortumab Vedotin
por: Hanna, Kirollos S.
Publicado: (2020)

Metastatic Penile Squamous Cell Carcinoma Responsive to Enfortumab Vedotin
por: Fahey, Catherine C., et al.
Publicado: (2023)

Case Report: Safety and Efficacy of Enfortumab Vedotin in a Patient With Metastatic Urothelial Carcinoma Undergoing Peritoneal Dialysis
por: Collette, Kaylyn R., et al.
Publicado: (2022)

Effect of Enfortumab Vedotin Dose Adjustment on Efficacy in Metastatic Urothelial Carcinoma: A Retrospective Single-Center Experience 
por: Clennon, Anna, et al.
Publicado: (2023)

Enfortumab Vedotin in Metastatic Urothelial Carcinoma: Survival and Safety in a European Multicenter Real-world Patient Cohort
por: Zschäbitz, Stefanie, et al.
Publicado: (2023)

Enfortumab vedotin and pembrolizumab as monotherapies and combination treatment in locally advanced or metastatic urothelial carcinoma: A narrative review
por: Bantounou, Maria A., et al.
Publicado: (2023)

A rare presentation of enfortumab vedotin–induced toxic epidermal necrolysis
por: Francis, Andrea, et al.
Publicado: (2020)

THU354 Enfortumab Vedotin Induced Refractory Hyperglycemia
por: Hussein, Marwah, et al.
Publicado: (2023)

Diabetic Ketoacidosis and Acute Kidney Injury Associated With Enfortumab Vedotin for Urothelial Carcinoma: A Case Report
por: Atemnkeng, Francis, et al.
Publicado: (2023)

Response of Patients with Taxane-Refractory Advanced Urothelial Cancer to Enfortumab Vedotin, a Microtubule-Disrupting Agent
por: Miyake, Makito, et al.
Publicado: (2023)

Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance
por: Klümper, Niklas, et al.
Publicado: (2023)

Somatic alterations of TP53 and MDM2 associated with response to enfortumab vedotin in patients with advanced urothelial cancer
por: Jindal, Tanya, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_bdl55i6pcut0fr111iird5kplh